Open AccessPOLYMIXIN IN ONCOLOGY CLINICAL PRACTICE
Author(s) -
Н. В. Дмитриева,
И. Н. Петухова,
Z. V. Grigorievskaya,
Н. С. Багирова,
И. В. Терещенко,
E. D. Grigorievsky
Publication year - 2018
Publication title -
sibirskij onkologičeskij žurnal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.115
H-Index - 4
eISSN - 2312-3168
pISSN - 1814-4861
DOI - 10.21294/1814-4861-2018-17-3-88-93
Subject(s) - acinetobacter baumannii , azithromycin , polymyxin , pseudomonas aeruginosa , medicine , antibiotics , rifampicin , colistin , polymyxin b , pneumonia , klebsiella pneumoniae , acinetobacter , microbiology and biotechnology , bacteria , biology , genetics , biochemistry , escherichia coli , gene
The purpose of the study was to present data on polymixin-based antibiotics with activity against infections caused by multidrug- resistant Gram-negative bacteria, such as Acinetobacter baumannii, Klebsiella pneumoniae, and Pseudomonas aeruginosa. Material and methods. The review includes data from clinical as well as in vitro studies for the period 1998–2017. The search for relevant sources was carried out in the Medline, Cochrane Library, Elibrary and other databases. Results. The analysis of the data showed the presence of synergism and additive activity of polymyxin in combination with carbapenems, rifampicin and azithromycin. However, experimental data showed no direct positive correlation between combination of polymyxim and azithromycin/ rifampicin. In clinical studies, in hospital-acquired pneumonia, including ventilator-associated pneumonia, the clinical response rate of polymyxin B combined with other antibiotics ranged from 38 % to 88 %. High nephro-and neurotoxicity of polymyxin observed in previous studies can be explained by a lack of understanding of its toxicodynamics or the use of an incorrect dose. Conclusion. Polymyxin B in combination with other antibiotics is a promising treatment against infectious complications caused by multidrug resistant Gram-negative bacteria.